CPRX Q4 2022 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$61M+58.6% YoY

Gross Profit

$50M81.6% margin

Operating Income

$31M50.7% margin

Net Income

$25M41.9% margin

EPS (Diluted)

$0.22

QoQ Revenue Growth

+6.1%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$40M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$376M

Total Liabilities

$75M

Stockholders' Equity

$300M

Cash & Equivalents

$298M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$61M	$38M	+58.6%
Gross Profit	$50M	$31M	+60.1%
Operating Income	$31M	$13M	+141.7%
Net Income	$25M	$9M	+173.6%

Revenue Segments

Product Revenue Net

$61M100%

License And Other Revenue

$74,0000%